Cargando…

Metabolomics, Microbiota, and In Vivo and In Vitro Biomarkers in Type 2 Severe Asthma: A Perspective Review

Precision medicine refers to the tailoring of therapeutic strategies to the individual characteristics of each patient; thus, it could be a new approach for the management of severe asthma that considers individual variability in genes, environmental exposure, and lifestyle. Precision medicine would...

Descripción completa

Detalles Bibliográficos
Autores principales: Caruso, Cristiano, Colantuono, Stefania, Nicoletti, Alberto, Arasi, Stefania, Firinu, Davide, Gasbarrini, Antonio, Coppola, Angelo, Di Michele, Loreta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541451/
https://www.ncbi.nlm.nih.gov/pubmed/34677362
http://dx.doi.org/10.3390/metabo11100647
_version_ 1784589233321672704
author Caruso, Cristiano
Colantuono, Stefania
Nicoletti, Alberto
Arasi, Stefania
Firinu, Davide
Gasbarrini, Antonio
Coppola, Angelo
Di Michele, Loreta
author_facet Caruso, Cristiano
Colantuono, Stefania
Nicoletti, Alberto
Arasi, Stefania
Firinu, Davide
Gasbarrini, Antonio
Coppola, Angelo
Di Michele, Loreta
author_sort Caruso, Cristiano
collection PubMed
description Precision medicine refers to the tailoring of therapeutic strategies to the individual characteristics of each patient; thus, it could be a new approach for the management of severe asthma that considers individual variability in genes, environmental exposure, and lifestyle. Precision medicine would also assist physicians in choosing the right treatment, the best timing of administration, consequently trying to maximize drug efficacy, and, possibly, reducing adverse events. Metabolomics is the systematic study of low molecular weight (bio)chemicals in a given biological system and offers a powerful approach to biomarker discovery and elucidating disease mechanisms. In this point of view, metabolomics could play a key role in targeting precision medicine.
format Online
Article
Text
id pubmed-8541451
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85414512021-10-24 Metabolomics, Microbiota, and In Vivo and In Vitro Biomarkers in Type 2 Severe Asthma: A Perspective Review Caruso, Cristiano Colantuono, Stefania Nicoletti, Alberto Arasi, Stefania Firinu, Davide Gasbarrini, Antonio Coppola, Angelo Di Michele, Loreta Metabolites Review Precision medicine refers to the tailoring of therapeutic strategies to the individual characteristics of each patient; thus, it could be a new approach for the management of severe asthma that considers individual variability in genes, environmental exposure, and lifestyle. Precision medicine would also assist physicians in choosing the right treatment, the best timing of administration, consequently trying to maximize drug efficacy, and, possibly, reducing adverse events. Metabolomics is the systematic study of low molecular weight (bio)chemicals in a given biological system and offers a powerful approach to biomarker discovery and elucidating disease mechanisms. In this point of view, metabolomics could play a key role in targeting precision medicine. MDPI 2021-09-22 /pmc/articles/PMC8541451/ /pubmed/34677362 http://dx.doi.org/10.3390/metabo11100647 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Caruso, Cristiano
Colantuono, Stefania
Nicoletti, Alberto
Arasi, Stefania
Firinu, Davide
Gasbarrini, Antonio
Coppola, Angelo
Di Michele, Loreta
Metabolomics, Microbiota, and In Vivo and In Vitro Biomarkers in Type 2 Severe Asthma: A Perspective Review
title Metabolomics, Microbiota, and In Vivo and In Vitro Biomarkers in Type 2 Severe Asthma: A Perspective Review
title_full Metabolomics, Microbiota, and In Vivo and In Vitro Biomarkers in Type 2 Severe Asthma: A Perspective Review
title_fullStr Metabolomics, Microbiota, and In Vivo and In Vitro Biomarkers in Type 2 Severe Asthma: A Perspective Review
title_full_unstemmed Metabolomics, Microbiota, and In Vivo and In Vitro Biomarkers in Type 2 Severe Asthma: A Perspective Review
title_short Metabolomics, Microbiota, and In Vivo and In Vitro Biomarkers in Type 2 Severe Asthma: A Perspective Review
title_sort metabolomics, microbiota, and in vivo and in vitro biomarkers in type 2 severe asthma: a perspective review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541451/
https://www.ncbi.nlm.nih.gov/pubmed/34677362
http://dx.doi.org/10.3390/metabo11100647
work_keys_str_mv AT carusocristiano metabolomicsmicrobiotaandinvivoandinvitrobiomarkersintype2severeasthmaaperspectivereview
AT colantuonostefania metabolomicsmicrobiotaandinvivoandinvitrobiomarkersintype2severeasthmaaperspectivereview
AT nicolettialberto metabolomicsmicrobiotaandinvivoandinvitrobiomarkersintype2severeasthmaaperspectivereview
AT arasistefania metabolomicsmicrobiotaandinvivoandinvitrobiomarkersintype2severeasthmaaperspectivereview
AT firinudavide metabolomicsmicrobiotaandinvivoandinvitrobiomarkersintype2severeasthmaaperspectivereview
AT gasbarriniantonio metabolomicsmicrobiotaandinvivoandinvitrobiomarkersintype2severeasthmaaperspectivereview
AT coppolaangelo metabolomicsmicrobiotaandinvivoandinvitrobiomarkersintype2severeasthmaaperspectivereview
AT dimicheleloreta metabolomicsmicrobiotaandinvivoandinvitrobiomarkersintype2severeasthmaaperspectivereview